Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 31 Jan 2021 Results of systemic review of 6 trials (Reck et al 2013, Reck et al 2016, IMpower 133, EA5161, KEYNOTE-604, CASPIAN) assessing difference in both efficacy and safety profiles among different Immuno-Oncology (IO) agents in combination with platinum-based CT in ES-SCLC patients according to different ICIs subtypes, presented at the 2020 World Conference on Lung Cancer.
    • 02 Aug 2012 Results in the cohort of patients with extensive SCLC published in the Annals of Oncology.
    • 13 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top